Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le).
CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is superb for staining of formalin-fixed, paraffin-embedded tissues.
Klonalität:
Monoclonal
Klon-Bezeichnung:
[SPM588]
Reinheit:
Affinity Chromatography
Formulierung:
Purified
Target-Kategorie:
CA19-9 / Sialyl Lewisa (GI Tumor Marker)
Application Verdünnung:
Flow Cytometry (1-2ug/million cells), Immunofluorescence (1-2ug/ml), Immunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT)(No special pretreatment is required for the immunohistochemical staining of formalin-fixed, paraffin-embedded tissue
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
